Moreover, SMF has shown the potential to synergize with clinically established TLR-4 agonists (e.g., MPLA) and immune checkpoint blockers such as anti-PD-L1, thereby further augmenting anti-tumor effects (Huo et al., 2024). Here, TLR4 is linked to neoplasm.